Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
- Registration Number
- NCT01658514
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Brief Summary
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In addition, this study compared the behavior of a single dose of Met DR with that of extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney function described above.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
-
18 to 80 (inclusive) years old at Visit 1 (Screening)
-
Male, or female and met all of the following criteria:
- Not breastfeeding
- Negative pregnancy test result at Visit 1 (Screening) (not applicable to postmenopausal or surgically sterile females)
- Surgically sterile, postmenopausal, or if of childbearing potential, practiced and was willing to continue to practice appropriate birth control during the entire duration of the study
- Body weight of ≥45 kg
-
Body mass index (BMI) of 18.0 to 40.0 kg/m² (inclusive) at Visit 1 (Screening)
-
Had type 2 diabetes mellitus and an HbA1c ≤10.0%
-
Had a physical examination with no clinically significant abnormalities as judged by the investigator
-
Estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation
-
Ability to understand and willingness to adhere to protocol requirements
-
Had End Stage Renal Disease requiring dialysis or severe renal dysfunction with eGFR <15 mL/min/1.73 m²
-
Was on dialysis or had been on dialysis within 12 months of Visit 1 (Screening)
-
Had received or planned to receive any iodinated contrast dye within 1 week prior to Visit 1 (Screening) or after study medication administration
-
Was taking or had taken within 1 week of Visit 1 cationic drugs that are eliminated by renal tubular secretion (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin)
-
Had a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
- Hepatic disease
- Gastrointestinal disease
- Endocrine disorder (type 2 diabetes mellitus was allowed)
- Cardiovascular disease
- Central nervous system diseases
- Psychiatric or neurological disorders
- Organ transplantation
- Chronic or acute infection
- Orthostatic hypotension, fainting spells or blackouts
- Allergy or hypersensitivity
-
Had any chronic disease requiring medication that had been adjusted in the past 14 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)
-
Had major surgery of any kind within 6 months of Visit 1 (Screening)
-
Had a clinically significant finding of an electrocardiogram (ECG) as assessed by the investigator at Visit 1 (Screening)
-
Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities, other than those related to diabetes or renal disease and other stable diseases, judged by the investigator to be clinically significant at Visit 1 (Screening)
-
Had a hemoglobin result <8 g/dL or a level indicating severe anemia of renal origin
-
Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
-
Had received Byetta® or short-acting insulin within 3 days of Visit 1 (Screening)
-
Had received metformin within 4 weeks of Visit 1 (Screening)
-
Had any drug treatment that affects gastrointestinal motility or gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid, within 2 days of Visit 2
-
Abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
-
Smoked more than 10 cigarettes, 3 cigars, or 3 pipes per day
-
Had donated blood within 2 months of Visit 1 (Screening) or was planning to donate blood during the study
-
Had received any investigational drug within one month (or seven half-lives of the investigational drug, whichever was greater) of Visit 1 (Screening)
-
Had known allergies or hypersensitivity to any component of study treatment
-
Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Met XR Met XR One dose of 1000 mg metformin extended-release Met DR Met DR One dose of 1000 mg metformin delayed-release Placebo Placebo One dose of Placebo
- Primary Outcome Measures
Name Time Method AUC (0-t) of Plasma Metformin from the time of dosing (0 h) to 72 hours postdose AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration
Cmax of Plasma Metformin from the time of dosing (0 h) to 72 hours postdose Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration
Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration from the time of dosing (0 h) to 24 hours postdose To determine the exposure-response relationship of metformin and plasma lactate concentrations
- Secondary Outcome Measures
Name Time Method